To the Editor I appreciated the nice review of the current status and promise for the use of next-generation sequencing (NGS) in identifying actionable somatic and germline molecular abnormalities as breast cancer therapeutic targets. The authors1(p262) conclude that “circulating tumor DNA analysis, once sensitive and broad enough” will enable the identification of these actionable abnormalities.
Sorscher S. Current Challenges Associated With Next-Generation Sequencing of Breast Cancer. JAMA Oncol. Published online May 18, 2017. doi:10.1001/jamaoncol.2017.0659